Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.

Author(s): Ernst T, Hoffmann J, Erben P, Hehlmann R, Hochhaus A, Müller MC

Publication: Clin Chem Lab Med, 2008, Vol. 46, Page 318-22

PubMed ID: 18303987 PubMed Review Paper? No

Purpose of Paper

Conclusion of Paper

Studies

1. Study Purpose

   This study compared PAXgene system stabilized bone marrow and blood specimens in regard to RNA yield, reference and target gene expression, and the prevalence of a gene mutation. Blood was collected directly into PAXgene tubes and frozen at -20°C after 2 h. Bone marrow was collected into EDTA or citrate syringes and tranferred to PAXgene tubes.

   Summary of Findings:

   Bone marrow specimens subjected to the PAXgene system for RNA stabilization generated greater RNA yields of comparable quality to those of corresponding blood specimens. Reference gene expression (total ABL, GUS) were significantly higher in bone marrow compared to blood specimens, while target BCR-ABL ratios did not differ among biospecimen locations. While BCR-ABL kinase domain mutation analysis generated concordant results for 93% of patients, the proportion of the mutation was significantly lower in bone marrow compared to blood (50 versus 70%).

   Biospecimens

   • Bodily Fluid - Bone Marrow
   • Bodily Fluid - Blood

   Preservative Types

   • PAXgene

   Diagnoses:

   • Neoplastic - Leukemia

   Platform:

   Analyte	Technology Platform
   RNA	Spectrophotometry
   RNA	Real-time qRT-PCR
   DNA	HPLC
   DNA	DNA sequencing

   Pre-analytical Factors:

   Classification	Pre-analytical Factor	Value(s)
   Biospecimen Acquisition	Biospecimen location	Bone marrow Blood

   View more